Table 4.
Association between BRCA1 and BRCA2 mutation status and clinicopathological characteristics a
| Clinical variables | BRCA1 carriers (n=55) | BRCA2 carriers (n=66) | Non-carriers (n=2454) | p Value† | p Value‡ |
| Age (year±SD) | 40.8±10.6 | 45.7±10.8 | 50.3±10.7 | <0.001 | 0.001 |
| Age distribution | |||||
| <30 | 9 (16.4) | 2 (3.1) | 56 (2.3) | <0.001 | 0.001 |
| 30–39 | 19 (34.5) | 20 (30.8) | 312 (12.9) | ||
| 40–49 | 15 (27.3) | 21 (32.3) | 785 (32.5) | ||
| 50–59 | 10 (18.2) | 12 (18.5) | 782 (32.4) | ||
| ≥60 | 2 (3.6) | 10 (15.4) | 478 (19.8) | ||
| Family history of breast cancer up to first degree | |||||
| No | 37 (67.3) | 47 (71.2) | 2143 (87.3) | <0.001 | <0.001 |
| Yes | 18 (32.7) | 19 (28.8) | 311 (12.7) | ||
| Family history of breast cancer up to second degree | |||||
| No | 32 (58.2) | 41 (62.1) | 1952 (79.5) | <0.001 | 0.001 |
| Yes | 23 (41.8) | 25 (37.9) | 502 (20.5) | ||
| Family history of ovarian cancer up to first degree | |||||
| No | 50 (90.9) | 63 (95.5) | 2429 (99.0) | <0.001 | 0.007 |
| Yes | 5 (9.1) | 3 (4.5) | 25 (1.0) | ||
| Family history of ovarian cancer up to second degree | |||||
| No | 49 (89.1) | 63 (95.5) | 2413 (98.3) | <0.001 | 0.078 |
| Yes | 6 (10.9) | 3 (4.5) | 41 (1.7) | ||
| Bilateral breast cancer | |||||
| No | 45 (81.8) | 60 (90.9) | 2321 (94.6) | <0.001 | 0.197 |
| Yes | 10 (18.2) | 6 (9.1) | 133 (5.4) | ||
| Ovarian cancer | |||||
| No | 53 (96.4) | 65 (98.5) | 2439 (99.4) | 0.007 | 0.362 |
| Yes | 2 (3.6) | 1 (1.5) | 15 (0.6) | ||
| Grade (%) | |||||
| I | 1 (2.8) | 0 | 236 (12.2) | <0.001 | 0.030 |
| II | 8 (22.2) | 25 (52.1) | 957 (49.4) | ||
| III | 27 (75.0) | 23 (47.9) | 746 (38.5) | ||
| Lymph node | |||||
| Negative | 30 (63.8) | 24 (44.4) | 1241 (56.6) | 0.320 | 0.076 |
| Positive | 17 (36.2) | 30 (55.6) | 953 (43.4) | ||
| Stage | |||||
| I | 10 (23.8) | 12 (23.5) | 614 (30.1) | 0.311 | <0.001 |
| II | 21 (50.0) | 18 (35.3) | 1042 (51.1) | ||
| III | 10 (23.8) | 13 (25.5) | 291 (14.3) | ||
| IV | 1 (2.4) | 8 (15.7) | 93 (4.6) | ||
| Oestrogen receptor | |||||
| Negative | 38 (80.9) | 11 (19.6) | 759 (33.6) | <0.001 | 0.028 |
| Positive | 9 (19.1) | 45 (80.4) | 1497 (66.4) | ||
| Progesterone receptor | |||||
| Negative | 36 (83.7) | 23 (44.2) | 875 (43.0) | <0.001 | 0.857 |
| Positive | 7 (16.3) | 29 (55.8) | 1161 (57.0) | ||
| Human epidermal growth factor 2 | |||||
| Negative | 43 (93.5) | 44 (84.6) | 1512 (70.5) | 0.001 | 0.027 |
| Positive | 3 (6.5) | 8 (15.4) | 632 (29.5) | ||
| Triple negative breast cancer | |||||
| No | 9 (22.0) | 43 (87.8) | 1626 (82.9) | <0.001 | 0.369 |
| Yes | 32 (78.0) | 6 (12.2) | 336 (17.1) | ||
| Ki-67 | |||||
| Low | 2 (33.3) | 4 (57.1) | 277 (64.1) | 0.119 | 0.703 |
| High | 4 (66.7) | 3 (42.9) | 155 (35.9) | ||
*Unless otherwise specified, data are presented in no. (%). For each data type, the total number of subjects may differ because of missing or incomplete data.
†BRCA1 carriers versus non-BRCA1/2 carriers.
‡BRCA2 carriers versus non-BRCA1/2 carriers.